|
Change of prognosis of patients with myelodysplastic syndromes during the last 30 years
|
Apr 2015
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria
|
Jan 2020
|
Haematologica
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Characterization of Myelodysplastic Syndromes (MDS) With T-cell Large Granular Lymphocyte Proliferations (LGL)
|
Jun 2020
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Characterization of TP53 Mutations in Low-Grade Myelodysplastic Syndromes and Myelodysplastic Syndromes with a Non-Complex Karyotype
|
Sep 2017
|
Eur J Haematol
|
myelodysplastic syndromes (MDS)
|
|
Chemical exposures and risk of acute myeloid leukemia and myelodysplastic syndromes in a population-based study
|
Sep 2016
|
Int J Cancer
|
myelodysplastic syndromes (MDS)
|
|
Chemoimmunotherapy's potential to impact paroxysmal nocturnal hemoglobinuria
|
Feb 2012
|
Clin Adv Hematol Oncol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia
|
Oct 2019
|
Blood Advances
|
aplastic anemia
|
|
Chronic fatigue in myelodysplastic syndromes: Looking beyond anemia
|
Jul 2020
|
Critical reviews in hematology/oncology
|
myelodysplastic syndromes (MDS)
|
|
Circulating microRNAs: promising biomarkers in aplastic anemia
|
Jan 2017
|
Haematologica
|
aplastic anemia
|
|
Clinical and biological implications of driver mutations in myelodysplastic syndromes.
|
Sep 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
